HopSo 400 mg (Tablet)
Unit Price: ৳ 450.00 (1 x 7: ৳ 3,150.00)
Strip Price: ৳ 3,150.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sofosbuvir |
| Company | Drug international ltd |
Indications
- Treatment of chronic hepatitis C infection
- Efficacy in subjects with HCV genotype 1, 2, 3, or 4 infection
- Monotherapy not recommended for treatment of CHC
- Treatment regimen and duration dependent on viral genotype and patient population
- Treatment response varies based on baseline host and viral factor
Pharmacology
- Nucleotide analog inhibitor
- Inhibition of HCV NS5B RNA-dependent RNA polymerase
- Intracellular metabolism to form pharmacologically active uridine analog triphosphate
- Incorporation into HCV RNA by the NS5B polymerase and acts as a chain terminator
Dosage & Administration
- One 400 mg tablet taken once daily with or without food
- Used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin
- Recommended combination therapy for different genotypes
- Consideration for CHC patients with genotype 1 infection who are Interferon ineligible
- Dose recommendation cannot be made for patients with severe renal impairment or end-stage renal disease
Interaction
- Reduced therapeutic effect with potent P-gp inducers in the intestine
- Potential serious symptomatic bradycardia when co-administered with amiodarone in combination with another direct-acting antiviral
Contraindications
- Contraindications applicable to combination therapies with Ribavirin or Peginterferon alfa/Ribavirin for pregnant women and their partners
Side Effects
- Common adverse events observed with HopSo in combination with Ribavirin and Peginterferon alfa and Ribavirin
Pregnancy & Lactation
- Pregnancy category B
- No adequate and well-controlled studies in pregnant women
- Unknown presence in human breast milk
Precautions & Warnings
- Risk of serious symptomatic bradycardia with amiodarone co-administration
- Cardiac monitoring recommended in specific patient groups
Use in Special Populations
- Safety and effectiveness in children less than 18 years of age not established
- Response rates observed for subjects over 65 years of age were similar to younger subjects
Overdose Effects
- No specific antidote available for overdose treatment
- General supportive measures including monitoring of vital signs
Therapeutic Class
- Hepatic viral infections (Hepatitis C)
Storage Conditions
- Keep out of the reach of children
- Keep in a cool & dry place
- Protect from light